Germany-based Merck searches partner in Brazil
A alemã Merck busca parceiro no Brasil
Intel ID : 219161
| Synopsis |
|
Germany-based Merck informed it's in negotiations with potential global partners to develop and market an immuno-oncology drug and plans to expand its partnerships in India and Brazil in the biosimilar industry. The group's CEO, Stefan Oschmann, said in a meting with analysts and investors that the company initiated a contest to select the best partner for its joint global development and commercialization process of anti-PD-L1 compound.
(content in portuguese)
A alemã Merck informou que está em tratativas com potenciais parceiros globais para desenvolver e comercializar um medicamento na área de imuno-oncologia e planeja ampliar suas parcerias na Índia e no Brasil no negócio de biossimilares. O executivo-chefe da unidade farmacêutica do grupo, Stefan Oschmann, comentou em encontro com analistas e investidores que a empresa iniciou uma concorrência para selecionar o melhor parceiro para o processo global conjunto de desenvolvimento e comercialização do composto anti-PD-L1. |
| Intel ID | 219161 | |
| Value | ND | |
| Native Currency |
US Dollar (USD)
Exchange Rate:  |
|
|
Financial Data - Merck Group
(31 Mar 2016) |
Revenue: EUR 3.665,00m EBITDA: EUR 1.282,00m Net Debt: EUR 12.072,00m |
|
| Date |
 |
|
| Country | |
|
| Region | ||
| Continent | |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Bidder
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.